Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 170
- Registration Number
- NCT03406000
- Locations
- 🇧🇷
Investigational Site Number 076011, Ribeirão Preto, Brazil
🇧🇷Investigational Site Number 076002, Goiânia, Brazil
🇧🇷Investigational Site Number 076006, São José dos Campos, Brazil
A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT03387657
- Locations
- 🇺🇸
Investigational Site Number 8400001, Dallas, Texas, United States
Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants
- Conditions
- Asthma
- Interventions
- Drug: Placebo for SAR440340Drug: Placebo for dupilumab
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 296
- Registration Number
- NCT03387852
- Locations
- 🇲🇽
Investigational Site Number 4840004, Durango, Mexico
🇺🇸Investigational Site Number 8400014, Milwaukee, Wisconsin, United States
🇺🇸Investigational Site Number 8400021, Ann Arbor, Michigan, United States
An Observational Study on Sarilumab-exposed Pregnancies
- Conditions
- Rheumatoid Arthritis -Exposure During Pregnancy
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 113
- Registration Number
- NCT03378219
- Locations
- 🇨🇦
CANADA, Canada, Canada
🇺🇸United States, New York, New York, United States
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 24
- Registration Number
- NCT03376802
- Locations
- 🇺🇸
Investigational Site Number 8400001, Orlando, Florida, United States
🇺🇸Investigational Site Number 8400002, Baton Rouge, Louisiana, United States
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
- Conditions
- Prostate CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT03367819
- Locations
- 🇨🇳
Investigational Site Number 1580002, Tainan, Taiwan
🇬🇧Investigational Site Number 8260001, Sutton, Surrey, United Kingdom
🇺🇸Investigational Site Number 8400007, Atlanta, Georgia, United States
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: INSULIN GLARGINE (HOE901)
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 384
- Registration Number
- NCT03359837
- Locations
- 🇨🇳
CHINA, China, China
A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)Drug: [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 13
- Registration Number
- NCT03350191
- Locations
- 🇸🇪
Investigational Site Number 7520001, Uppsala, Sweden
Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years
- Conditions
- InfluenzaFlu
- Interventions
- Biological: Hualan TIVBiological: SP Shz TIV
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1600
- Registration Number
- NCT03344029
- Locations
- 🇨🇳
Sanofi Pasteur Investigational Site 001, Huai'an, China
Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
- Conditions
- Neoplasm Malignant
- Interventions
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 34
- Registration Number
- NCT03324113
- Locations
- 🇯🇵
Investigational Site Number 3920002, Nagoya-Shi, Japan
🇯🇵Investigational Site Number 3920003, Kashiwa-Shi, Japan
🇯🇵Investigational Site Number 3920001, Sunto-Gun, Japan